Biotech | August 20, 2021
Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
National Accreditation Board for Hospitals & Healthcare Providers (NABH) is a constituent board of the Quality Council of India, set up to establish and operate accreditation programmes for healthcare organisations
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The company is eligible for 12 months exclusivity from launch
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
